. . "chronic myelogenous leukemia; CML; imatinib mesylate; intemittent therapy; Bcr/Abl"@en . "Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent dosage of IM in order to avoid prolonged interruptions in therapy, to allow spontaneous recovery in blood count and, simultaneously, to achieve intermittently therapeutic plasma drug levels. A retrospective analysis of intermittent therapy (iT) in 12 patients with CML is presented. All patients had intermediate-to-high prognostic scores. Two patients had history of autologous stem cell transplantation. Initial standard therapy with IM was indicated for resistance to interferon (eight subjects) and for accelerated phase in four cases (one of them cytogenetic) and lasted for 1 - 6 months. iT with 300 - 600 mg of IM 1 - 5 times a week was started after significant hematologic toxicity occurre"@en . "Divok\u00FD, Vladim\u00EDr" . "9"^^ . . . . "47" . . . "7"^^ . "Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent dosage of IM in order to avoid prolonged interruptions in therapy, to allow spontaneous recovery in blood count and, simultaneously, to achieve intermittently therapeutic plasma drug levels. A retrospective analysis of intermittent therapy (iT) in 12 patients with CML is presented. All patients had intermediate-to-high prognostic scores. Two patients had history of autologous stem cell transplantation. Initial standard therapy with IM was indicated for resistance to interferon (eight subjects) and for accelerated phase in four cases (one of them cytogenetic) and lasted for 1 - 6 months. iT with 300 - 600 mg of IM 1 - 5 times a week was started after significant hematologic toxicity occurre" . "15110" . . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Veselovsk\u00E1, Jitka" . "9"^^ . "Egorin, Merrill J." . . "6" . "Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing" . "P\u0159eru\u0161ovan\u00E9 d\u00E1vkov\u00E1n\u00ED imatinibu u CML pacient\u016F se signifikantn\u00ED hematologickou toxicitou po standardn\u00EDm d\u00E1vkov\u00E1n\u00ED"@cs . "Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing"@en . . . . "Jaro\u0161ov\u00E1, Marie" . . . . "Hematologick\u00E1 toxicita je jedn\u00EDm z nejv\u00FDzamn\u011Bj\u0161\u00EDch probl\u00E9m\u016F p\u0159i l\u00E9\u010Db\u011B chronick\u00E9 myeloidn\u00ED leukemie pomoc\u00ED imatinib mesyl\u00E1tu (IM). V t\u00E9to situaci je doporu\u010Dov\u00E1no vysazen\u00ED l\u00E9ku nebo aplikace r\u016Fstov\u00FDch faktor\u016F. Tato studie uv\u00E1d\u00ED nov\u00FD p\u0159\u00EDstup spo\u010D\u00EDvaj\u00EDc\u00ED ve vyu\u017Eit\u00ED p\u0159eru\u0161ovan\u00E9ho pod\u00E1v\u00E1n\u00ED IM ..."@cs . . "Faber, Edgar" . "Indr\u00E1k, Karel" . "Ro\u017Emanov\u00E1, \u0160\u00E1rka" . "RIV/61989592:15110/06:00003101!RIV09-MZ0-15110___" . "Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing" . . "Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing"@en . . "Holzerov\u00E1, Milena" . "P\u0159eru\u0161ovan\u00E9 d\u00E1vkov\u00E1n\u00ED imatinibu u CML pacient\u016F se signifikantn\u00ED hematologickou toxicitou po standardn\u00EDm d\u00E1vkov\u00E1n\u00ED"@cs . "[23D8E7BAB831]" . . . . "1042-8194" . "RIV/61989592:15110/06:00003101" . . "Mare\u0161ov\u00E1, Ivana" . . . "Leukemia & lymphoma" . . "P(GA301/04/1239), P(NR7870), Z(MSM6198959205)" . "480111" .